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Abstract
Ewing’s sarcoma is a malignant pediatric bone tumor with a poor prognosis for patients with
metastatic or recurrent disease. Ewing’s sarcoma cells are acutely hypersensitive to poly
(ADP-ribose) polymerase (PARP) inhibition and this is being evaluated in clinical trials,
although the mechanism of hypersensitivity has not been directly addressed. PARP inhibi-
tors have efficacy in tumors with BRCA1/2mutations, which confer deficiency in DNA dou-
ble-strand break (DSB) repair by homologous recombination (HR). This drives dependence
on PARP1/2 due to their function in DNA single-strand break (SSB) repair. PARP inhibitors
are also cytotoxic through inhibiting PARP1/2 auto-PARylation, blocking PARP1/2 release
from substrate DNA. Here, we show that PARP inhibitor sensitivity in Ewing’s sarcoma cells
is not through an apparent defect in DNA repair by HR, but through hypersensitivity to
trapped PARP1-DNA complexes. This drives accumulation of DNA damage during replica-
tion, ultimately leading to apoptosis. We also show that the activity of PARP inhibitors is
potentiated by temozolomide in Ewing’s sarcoma cells and is associated with enhanced
trapping of PARP1-DNA complexes. Furthermore, through mining of large-scale drug sensi-
tivity datasets, we identify a subset of glioma, neuroblastoma and melanoma cell lines as
hypersensitive to the combination of temozolomide and PARP inhibition, potentially identify-
ing new avenues for therapeutic intervention. These data provide insights into the anti-can-
cer activity of PARP inhibitors with implications for the design of treatment for Ewing’s
sarcoma patients with PARP inhibitors.
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Introduction
Ewing’s sarcoma is a malignant bone tumour in which 85% of patients harbour a gene translo-
cation involving the Ewing’s sarcoma breakpoint region 1 (EWS) gene fused to the Friend leu-
kaemia virus integration site 1 (FLI1) gene: EWS-FLI1 t(11;22) [1, 2]. The translocation
encompasses the N-terminal transcriptional activation domain of EWS and the C-terminal
DNA binding domain of FLI1, which drives cellular transformation [1]. First-line treatment
for Ewing’s sarcoma involves multidrug chemotherapy, radiotherapy, and/or surgical excision
of the primary tumor, and is associated with high morbidity [3]. Moreover, 25% of patients
present with metastatic disease and many relapse [4]. Prognosis is poor for these patients, with
5-year overall survival rates of 30% for patients with late recurrence, and 7% for patients who
experience early recurrence [5, 6]. There is therefore a need for more targeted regimes with
reduced treatment associated morbidity and long-term survival benefit of patients with Ewing’s
sarcoma.
We previously reported a large-scale unbiased drug sensitivity screen in an extensive cancer
cell line panel, and identified hypersensitivity of Ewing’s sarcoma cells (EWSCs) to distinct
PARP inhibitor (PARPi) chemotypes [7]. Poly (ADP-ribose) polymerases (PARPs) comprise a
group of ADP-ribosyl transferase enzymes, which transfer ADP-ribose from NAD+ onto their
target proteins (PARylation), thereby regulating a wide array of cellular processes [8]. PARP1
and the related protein PARP2 are involved in repairing DNA single-strand breaks (SSBs).
SSBs drive PARP1/2 (hereafter referred to as PARP) binding to DNA, catalysing a series of
PARylation events that promote DNA repair processes [8]. Through its involvement in SSB
repair, PARP has been exploited therapeutically. Olaparib, a potent PARPi, exhibits synthetic
lethality in cells with BRCA1/2mutations, which confer deficiency in DNA double-strand
break (DSB) repair mediated by homologous recombination (HR) [9, 10]. These cells have a
high dependency on PARP1 and its role in SSB repair, and consequently they are hypersensi-
tive to PARP inhibition. Olaparib has anti-tumour activity in BRCA-mutant breast, ovary and
prostate cancers [9, 11–14]. Additional genetic modulators of PARPi sensitivity have been
identified, such as mutations in the genes encoding ATM, ATR or PTEN, and elevated PARP1
expression is emerging as a measure of PARPi sensitivity [15–18].
Another mechanism of cytotoxicity has also been described for PARPi. By catalytically
inhibiting PARP, PARPi also block auto-PARylation by PARP, required for its dissociation
from DNA [19–21]. Thus, PARP inhibition can lead to the formation of cytotoxic trapped
PARP-DNA complexes and the accumulation of DSBs. The ability of PARPi to trap PARP dif-
fers among PARPi, and is not solely linked to their ability to catalytically inhibit PARP [22, 23].
Following the observation that the EWS-FLI1 genotype may serve as a biomarker for PARPi
sensitivity, a clinical trial was initiated testing single-agent olaparib in Ewing’s sarcoma patients
with recurrent disease, but clinical response endpoints were not met [24–27]. More recently,
PARPi in combination with the DNA alkylating agent temozolomide has been shown to have
potent anti-tumour activity in Ewing’s sarcoma xenograft and orthotopic models [24, 28, 29],
and multiple clinical trials are currently evaluating the combination of PARPi together with
temozolomide.
In order to inform on opportunities for implementing PARPi in the treatment of Ewing’s
sarcoma, we investigated the underlying mechanism of PARPi hypersensitivity in EWSCs.
Notably, the mechanism of PARPi sensitivity in EWSCs has hitherto not been directly evalu-
ated despite the potent activity of PARPi in vitro and in vivo. Our study provides evidence that
PARPi sensitivity in Ewing’s sarcoma is not due to an apparent defect in HR-mediated DNA
repair, and instead is associated with acute sensitivity to trapped PARP-DNA complexes. Fur-
thermore, we identify a subset of glioma, neuroblastoma and melanoma cells that are
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particularly sensitive to a combination of temozolomide and PARPi, thereby potentially
extending the clinical use of PARPi.
Materials and Methods
Cell lines and compounds
See supplementary methods (S1 Text) for a complete list of cell lines and culture conditions.
Compounds were purchased from commercial vendors and stored as aliquots at -80°C sub-
jected to a maximum of five freeze-thaw cycles.
Drug sensitivity data
An unpaired two-sample t-test was performed on the natural log of IC50s of EWS-FLI1-mutant
and wild-type cells with 95% confidence intervals using GraphPad Prism. We have included a
table of cell line drug sensitivity data for the inhibitors used in this study (S1 Data). Genomic
characterization of cell lines and generation of drug sensitivity data was performed as previ-
ously described [7].
Cellular assays
Long term cell growth assays were conducted as previously described [7]. OLAR5 cells were
generated by serial drug exposure [30]. Cells were assayed and drug treated in 96-well plates
[7]. Cell viability was measured after 72h using Cell Titer Blue (Promega) or sulphorhodamine
(SRB) colorimetric assay (Sigma), and apoptosis after 48h using ApoOne (Promega) as per
manufacturer’s instructions. IC50s and concentrations for 50% of maximal inhibition of cell
proliferation (GI50) were determined using GraphPad Prism software.
For combination drug screening, cells were plated in 384-well plates and drugs added in a
5x5 4-fold drug dilution matrix for 72h using robotics. Cells were analyzed using Syto60 (Invi-
trogen) and quality control performed as previously described [7].
Immunofluorescence
For immunofluorescent analysis on the Cellomics Arrayscan (Thermo Fisher Scientific), cells
were plated and treated on 96-well plates, fixed and permeabilized with 4% paraformaldehyde/
0.1% Triton-X-100/PBS and washed with PBS. Cells were blocked (2%BSA/PBS) and incubated
with 0.4μg/ml anti-γH2AX antibody (05–636; Millipore). Cells were washed (0.1% Tween/
H2O) and incubated with 4μg/ml Alexa 488-labelled secondary antibody and 4μg/ml Hoechst
(Sigma-Aldrich). Cells were washed and overlaid with PBS. All images were captured at 40x
magnification and analyzed using the spot detector bioapplication. Cells were gated as positive
for γH2AX with 4–5 foci per nucleus.
For confocal microscopy, cells were split onto coverslips in 6-well plates, labeled with 5μM
EdU for 15 minutes prior to drug treatment, fixed (4% paraformaldehyde/PBS) and permeabi-
lized (0.2% Triton/PBS). EdU was detected by Click-IT (Life Technologies). Cells were washed
with PBS and coverslips treated with DNaseI for 2h in a 37°C humidified container. Cells were
washed and blocked (1% BSA/2% FCS/PBS) and stained with 0.2μg/ml anti-RAD51 antibody
(H-92; Santa Cruz Biotechnologies) and 0.2μg/ml anti-γH2AX antibody (05–636; Millipore)
overnight. Cells were washed with PBS, stained with 4μg/ml Alexa 555-labelled secondary anti-
body then washed and stained with 1μg/ml DAPI (Sigma) on a rocking platform. Each cover-
slip was rinsed in distilled water, blotted dry and mounted onto a slide by inverting into a drop
of vectashield (Vector Laboratories) and analysed on an Olympus confocal microscope and a
Deltavision fluorescence microscope with 40x and 100x objectives respectively.
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Western immunoblotting
See supplementary methods (S1 Text) for details of cell lysate preparation, quantification and
antibodies used. Cellular sub-fractionation assays were performed using a kit as per manufac-
turer’s instructions (Thermo Fisher Scientific).
siRNA depletions
Cells were either mock-transfected or transfected with a scrambled negative control (Ambion),
siPARP1_1 (CCAUUGAGCACUUCAUGAA; Sigma), siPARP1_2 (GAUAGAGCGUGAAGGCGAA;
Sigma), siCtIP (GCUAAAACAGGAACGAAU) or siBRCA1 (GGAACCUGUCUCCACAAG) in a
reverse format using RNAiMax (Life Technologies). To determine depletion efficiency, cells
were transfected in 6-well plates and lysed at the time of drug treatment (18h post-transfec-
tion). Otherwise cells were transfected in 96-well plates, drug treated 18h post-transfection and
viability assays performed 96h post-drug treatment whereas cells were fixed for immunofluo-
rescent analysis 8h post-drug treatment. For assessment of olaparib sensitivity following
BRCA1 and CtIP depletion, cells were drug treated 48h post-transfection and assayed 96h
later.
Results
EWSCs are hypersensitive to PARP inhibition and S-phase DNA-
damaging agents
We previously performed a large-scale drug sensitivity screen in>400 cancer cell lines and
identified a marked hypersensitivity of EWSCs to PARP inhibition [7]. This sensitivity was
detected in a 72-hour assay and resulted in apoptosis. Here, we extend these results by screen-
ing>950 cancer cell lines against the PARPi olaparib (AZD-2281), rucaparib (AG-014699),
veliparib (ABT-888) and BMN-673 [31–35]. To validate EWS-FLI1 as a marker of sensitivity,
we confirmed disruption of the EWS gene in all the EWSCs in our cell panel (S1A Fig). These
studies confirmed a marked hypersensitivity of EWSCs to three of the four PARPi (BMN
673> olaparib> rucaparib) (Fig 1A). This was validated in 10–14 day long term cell growth
assays, and sensitivity was observed at concentrations as low as 7nM for BMN-673, and 600nM
for olaparib and rucaparib (Fig 1B) [7]. In contrast, veliparib showed only marginal activity
against EWSCs in our screen, and in long term growth assays we observed only partial sensitiv-
ity at 1.2–10μM (Fig 1A and 1B). In this regard, we note that, despite veliparib potently inhibit-
ing PARP catalytic activity at concentrations>1 μM it has reduced trapping efficiency
compared to other PARP inhibitors [22].
We found that EWSCs are also markedly hypersensitive to S-phase DNA-damaging agents
including camptothecin analogs, bleomycin, cisplatin, gemcitabine and doxorubicin (Fig 1C
and S1B Fig) [7]. However, sensitivity to inhibitors of other DNA-damage response (DDR)
components including ATM, ATR, DNA-PK, CHK1 or CHK2 was not observed (data not
shown). Thus, EWSCs are specifically hypersensitive to PARPi and S-phase DNA-damaging
agents.
Olaparib induces DNA DSBs despite functional DDR and HR in EWSCs
We sought to investigate the mechanism of sensitivity of EWSCs to PARP inhibitors, focusing
on a representative cell line ES8 and the clinically approved drug LynparzaTM (olaparib) [36].
We verified our results by using multiple different PARPi with additional EWSC lines
(MHH-ES-1 and ES7). Whole-exome sequencing of EWSCs did not identify mutations in
DNA repair genes as a possible reason for the observed sensitivity (sequencing data available
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on COSMIC) [37]. We examined levels of DDR proteins including ATM, ATR, 53BP1, CHK1,
CHK2, MRE11, BRCA1 and BRCA2 by western immunoblotting, all of which were expressed
in EWSCs (S2A and S2B Fig).
We then characterized the effect of olaparib on genome integrity. Serine-139 phosphory-
lated histone H2AX (γH2AX), a marker of DNA DSBs, was rapidly induced within 2 hours of
olaparib treatment and steadily increased over 24 hours, and this response was dose-dependent
(Fig 2A and 2B and S3A Fig). Induction of 53BP1 foci was also observed, suggestive of on-
going DNA repair (S3B Fig). Notably, blocking entry into S-phase of the cell cycle with a
CDK4/6 inhibitor (palbociclib), or inhibiting replication with aphidicolin, prevented
Fig 1. EWSCs are sensitive to PARP inhibition and S-phase DNA-damaging agents. (A) and (C) Scatter
plots of IC50 (μM) values on a log scale comparing drug sensitivity of EWS-FLI1-positive and wild-type (WT)
EWS-FLI1-negative cell lines to (A) four PARPi and (C) camptothecin and cisplatin. The sample size (n) is
indicated and each circle represents the IC50 of one cell line. The red bar is the geometric mean and the drug
name is depicted above each plot along with the significance of the association as determined by an unpaired
two-sample t-test. (B) Long term viability assays in EWSCs were performed in the presence of vehicle (-) or
increasing concentrations of four PARPi as indicated. Non-EWSC lines (U-2-OS and HeLaSF) are included
for comparison. These data are representative of 3 independent experiments.
doi:10.1371/journal.pone.0140988.g001
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accumulation of γH2AX following olaparib treatment, indicating that progression into S-phase
and on-going replication are necessary for overt induction of DNA damage by olaparib in
EWSCs (Fig 2B and 2C and S3A and S3C Fig).
We then examined whether the ATM and ATR pathways involved in signaling DNA dam-
age were functional in EWSC. ATM is typically activated in response to DSBs, promotes DSB
exonuclease processing, and activates an S-phase checkpoint [38]. ATR slows down S-phase
progression and mitotic entry, to enable protection and restart of stalled replication forks. In
ES8 cells, olaparib treatment induced autophosphorylation of ATM (Ser-1981), and phosphor-
ylation of its downstream targets KAP1 (Ser-824) and CHK2 (Thr-68) (Fig 3A). We also
observed phosphorylation of RPA (Ser-4/8), an early marker of DSB-resection and HR, as well
as activation of CHK1 (phosphorylated Ser-345), both of which are DDR markers associated
with ATR activation. KAP1 Ser-473 is phosphorylated by CHK1, and was also induced [39].
Similar results were observed in multiple EWSCs, and also in response to camptothecin, which
induces DSBs by trapping topoisomerase I (Fig 3B and S4A Fig). Collectively, these data indi-
cated that ATR and ATM signaling are functional in EWSCs.
A key step in HR is recruitment of RAD51 to sites of DNA damage, facilitating homology
search and recombination, an event notably impaired in cancer cells that harbor deficiencies in
HR [10]. Following olaparib treatment of EWSCs, we observed induction of RAD51 foci in S-
phase cells, labeled by EdU-incorporation during drug treatment, suggesting that HR is func-
tional to a late stage in such cells and further demonstrating that DSBs accumulate in actively
replicating EWSCs (Fig 3C and S3D Fig). To further test the proficiency of HR in EWSCs, we
depleted critical HR proteins, BRCA1 and CtIP (or RBBP8), by siRNA [40]. Notably, although
EWSCs are hypersensitive to PARPi, four representative EWSCs were further sensitized to
Fig 2. Olaparib induces DNA DSBs in S-phase of the cell cycle in EWSCs. (A) ES8 cells were treated
with vehicle or olaparib and stained with Hoechst (nucleus; blue) and for γH2AX (DSBs; green). Images on
the left are of the 8-hour time point. The graph measures fold increase in γH2AX responders at the time points
indicated. Error bars represent the standard deviation of the mean of technical triplicates. (B) ES8 cells were
treated with olaparib for 16 hours following a 6-hour pre-treatment with palbociclib (CDK4/6i) or vehicle and
percentage of γH2AX responders determined. (C) ES8 cells were treated with vehicle, 5μM aphidicolin
(AphD), 5μM olaparib (Ola) or a 30-minute pre-treatment with aphidicolin followed by olaparib for 8 hours and
percentage of γH2AX responders determined. Asterisks indicate student’s paired t-test P value *P<0.05,
**P<0.01, ns = not significant, relative to control. These data are representative of 3 independent
experiments.
doi:10.1371/journal.pone.0140988.g002
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olaparib by depletion of BRCA1 or CtIP, revealing that these factors act in EWSCs to mitigate
olaparib toxicity (Fig 3D). Thus, although we cannot completely exclude a defect in the DDR
in EWSCs, our results demonstrate that HR is at least partially operational in EWSCs, and that
ATM and ATR DDR pathways involved in detecting, signaling and responding to DNA dam-
age are functional. Notably, further support for functional repair pathways in EWSCs comes
from the exceptionally low burden of mutations and structural variation observed in the
tumours of Ewing’s sarcoma patients compared to other malignancies [41].
EWSCs are hypersensitive to PARP1 trapping
The hypersensitivity of EWSCs to multiple PARPi and the absence of an apparent DDR defect
suggested that PARP trapping underpins sensitivity. To test this, we depleted PARP1 with
siRNA and measured the effect on viability in ES8 cells. PARP1 siRNA efficiently depleted
PARP1 in ES8 cells but depletion alone had little effect on viability (Fig 4A black columns and
S4B Fig). Notably, however, PARP1 depletion reversed the sensitivity of ES8 cells towards ola-
parib and also the structurally and chemically distinct PARPi rucaparib (Fig 4A white columns
and S4C Fig), and by using a titration of PARP1 siRNA we observed that the extent of the
reversal correlated with PARP1 expression levels (Fig 4B). Similar effects were observed in ES7
and MHH-ES-1 cells, and when using two different siRNA targeting PARP (S4B, S4D and S4E
Fig). Moreover, we generated a PARPi-resistant clone of ES8 cells by serial olaparib exposure,
named OLAR5, which had substantially enhanced resistance to multiple PARPi compared to
parental cells (Fig 4C). Strikingly, we found that OLAR5 cells had strongly down-regulated
PARP1 protein expression (Fig 4D), further suggesting that PARP1 protein is required for the
Fig 3. DNA DSB repair by HR is functional in EWSCs. (A)Western blot of ES8 cells treated with olaparib
for the times indicated. Markers are grouped as part of ATM or ATR signaling. Tubulin served as a loading
control. (B)Western blot of ES8 cells treated with camptothecin and harvested at various time points
following drug washout. GAPDH served as a loading control. (C) Percentage of EdU-positive and EdU-
negative ES8 cells with >5 nuclear RAD51 foci following 6-hour treatment with vehicle or olaparib (ola). (D)
Olaparib log GI50 (μM) of cell lines mock-transfected or transfected with CtIP or BRCA1 siRNA as indicated.
doi:10.1371/journal.pone.0140988.g003
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toxicity of PARPi in EWSCs and consistent with sensitivity observed in prostate cancer and
chicken DT40 cells where PARP trapping is operative [22].
PARP inhibition in combination with DNA alkylating agents has potent anti-tumour activ-
ity in Ewing’s sarcoma xenograft and orthotopic models [24, 29], and the use of PARP inhibi-
tors (olaparib, niraparib and BMN-673) with temozolomide is currently being evaluated in
clinical trials (NCT02044120, NCT01858168 and NCT02116777). Thus, we decided to investi-
gate whether the underlying mechanism of sensitivity to this combination was also driven by
hypersensitivity to PARP trapping and if so, whether PARP trapping was only enhanced by
alkylating agents or also by other S-phase damaging agents with different modes-of-action.
The DNA alkylating agent methyl methane sulfonate (MMS) drives accumulation of
methyl-DNA adducts, repair of which is promoted by PARP DNA-binding and enhances
PARP trapping [22, 23, 42]. Thus, to evaluate whether S-phase DNA damaging agents enhance
PARP1 trapping in EWSCs, we performed a screen of multiple PARPi (rucaparib, niraparib
and BMN-673) in combination with three clinically used S-phase damaging agents with dis-
tinct modes-of-action (cisplatin, temozolomide and camptothecin), and included MMS as a
positive control. Niraparib was selected because it was the only PARPi in clinical trials with
temozolomide at the time of this study, and rucaparib and BMN-673 were selected because
they are potent PARP trappers [22, 23]. We screened four EWSCs (ES7, ES8, MHH-ES-1,
A673), the ES8-derived PARPi-resistant line OLAR5, one BRCA1-mutant (MDA-MB-436)
and two non-Ewing’s control lines (DU-145 and U-2-OS). EWSCs were very sensitive to camp-
tothecin alone, and a combination with PARPi failed to enhance sensitivity at the doses tested
(Fig 5A and S5 Fig). Similarly, EWSCs were very sensitive to cisplatin alone but some further
sensitization was observed in combination with PARPi in some EWSC cell lines. Importantly,
temozolomide more substantially enhanced sensitivity to PARPi in all EWSCs tested, doing so
to a degree comparable with MMS (Fig 5A and S5 Fig). For example, whereas treatment with
0.5μM niraparib had little effect on EWSCs, combination with 200μM temozolomide led to an
almost complete loss of cell viability in all EWSCs tested (Fig 5B). The enhanced sensitivity
with temozolomide was observed with multiple PARPi (niraparib, rucaparib, olaparib and
Fig 4. EWSCs are sensitive to PARP1 trapping. (A) Relative viability of mock-transfected and PARP1 siRNA-transfected ES8 cells treated with vehicle or
olaparib. Asterisks indicate student’s paired t-test P value **P<0.01, ns = not significant. (B) PARP1 expression in cells transfected with a scrambled control
or a titration of PARP1_1 siRNA and their relative viability following treatment with vehicle or olaparib. (C) IC50 values of parental ES8 and PARPi-resistant
OLAR5 cells to five different PARPi and the fold difference between them. (D)Western blot of PARP1 expression in ES8 and OLAR5 cells. Viability values
are the mean of technical triplicates and representative of 3 independent experiments.
doi:10.1371/journal.pone.0140988.g004
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BMN-673) and in all EWSC lines tested (Fig 5B and S5 and S6A Figs). The combination of ola-
parib with temozolomide induced apoptosis within 48 hours (Fig 5C).
The enhanced sensitivity to PARPi in combination with temozolomide was not specific to
EWSCs. In DU-145 cells we observed sensitivity comparable with EWSCs, and PARP inhibi-
tion marginally potentiated the effects of temozolomide treatment in U-2-OS cells (S6B Fig).
By contrast, when compared with the parental line ES8, neither MMS nor temozolomide
enhanced sensitivity to PARPi in the PARPi-resistant EWSC, OLAR5, which had down-regu-
lated PARP1 expression (S6C Fig).
To determine whether temozolomide and PARP1 inhibition enhanced the trapping of
PARP1, we used a cellular sub-fractionation assay. We were unable to detect an increase in
Fig 5. Temozolomide enhances olaparib-induced PARP1 trapping. (A) Heatmaps (left panel) of relative viability values of ES8 cells screened against a
combination of niraparib and one of three chemotherapies or MMS. High viability values are in red and low viability values in green. Graphs (right panel) show
the corresponding dose response curves measuring relative viability with a separate line plotted for each concentration of the combined drug. The dose
response for niraparib alone is highlighted in red. Viability values are the mean of technical duplicates. (B) Relative viability of EWSCs treated with vehicle,
niraparib (0.5uM) or temozolomide (TMZ) alone (200uM), or in combination. The combination effect is highlighted in green. (C) Fold induction of caspase 3/7
activation in EWSCs following treatment with vehicle, olaparib or temozolomide alone or in combination for a total of 48 hours. A student’s paired t-test was
performed and significance values are indicated. (D) Cellular sub-fractionation assay following treatment of EWSCs with vehicle (-), MMS in combination with
olaparib (ola), or olaparib and temozolomide (TMZ) alone or in combination for 4 hours.
doi:10.1371/journal.pone.0140988.g005
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PARP1-DNA complexes with PARPi alone, or at concentrations at which enhanced sensitivity
was detected in viability assays, likely due to lack of sensitivity of the trapping assay. However,
1mM temozolomide and 10μM olaparib drove PARP1 trapping on chromatin to detectable
levels, confirming that temozolomide enhanced PARP1 trapping by PARPi (Fig 5D, PARP1
lanes 6 and 10). The lack of sensitivity of the trapping assay is demonstrated by the fact that
MMS strongly potentiated the effects of olaparib on cell viability at concentrations of 0.0001%
and 0.5μM respectively (S6D Fig), whereas PARP1-DNA complexes were only detected at 10–
100 fold higher concentrations (0.01% MMS and 5μM olaparib; Fig 5D and S6E Fig). In aggre-
gate, these data suggested that the toxicity of PARPi in EWSCs is due to cytotoxic PARP1 trap-
ping, and that the combination with DNA alkylating agents, such as MMS or temozolomide,
likely enhances toxicity through increased PARP1 trapping.
Temozolomide enhances PARP inhibitor sensitivity in multiple tumour
types
Having observed that the enhanced effect of PARPi with temozolomide extended to non-
EWSC cells, such as U-2-OS and DU-145, we re-analyzed our drug sensitivity data (S2 Data)
to identify other cell lines that might be particularly sensitive to this combination. Thus, we
identified cell lines with a similar drug sensitivity profile to EWSCs, in particular with IC50 val-
ues>1.5 standard deviations lower than the mean for olaparib, BMN-673 and camptothecin,
and cross-sensitivity to at least two of these inhibitors. These criteria enriched for 42 non-
EWSC cell lines (of 840 cell lines with a complete dataset; 6%) primarily from nervous system
(glioma and neuroblastoma), lung, blood and ovary, and to a lesser extent cell lines from vari-
ous other tissue types, such as melanoma (S2 Data). A subset of candidate cell lines (n = 14)
was screened with a combination of olaparib with temozolomide, and enhanced sensitivity was
observed in 6 of 8 nervous system cell lines and in both melanoma cell lines tested (Fig 6 and
S7A Fig). By contrast, we observed at most additive effects in lung cell lines tested (4 of 4 lines).
Thus, sensitivity to PARPi, enhanced by combination with temozolomide, may be prevalent in
a subset of cells within multiple tumour types. Indeed, when we performed sub-fractionation
assays in three nervous system and two melanoma cell lines, we detected PARP1-DNA com-
plexes in all (S7B Fig, compare lanes 6 and 10). Interestingly, we detected trapped PARP1-DNA
complexes in U251 glioma cells, which did not meet our drug sensitivity criteria and also did
not have enhanced sensitivity to the combination of olaparib with temozolomide, indicating
that PARP-DNA complexes are not toxic to all cells (S7C and S7D Fig, compare lanes 6 and
10).
Discussion
PARP inhibition elicits anti-tumour activity in BRCA-mutant HR-deficient cancers [9–14],
due to the dependency of these cancers on PARP1 activity in SSB repair to avoid replication-
dependent accumulation of DSBs. Here, we confirm, using an expanded dataset, that EWSCs
are hypersensitive to multiple PARPi chemotypes [31–35]. Olaparib treatment led to activation
of DDR pathways and formation of RAD51 foci (a marker for functional HR), and depletion of
HR proteins enhanced olaparib sensitivity. We did not identify aberrations by exome sequenc-
ing or western blotting in any of the established DDR proteins tested. Thus, although we are
unable to exclude an underlying DNA repair defect, our results suggest that DSB repair by HR
in EWSC lines is at least partially operative. This is consistent with an exceptionally low burden
of mutations and structural variation in Ewing’s sarcoma patient tumours, which is in contrast
to tumors deficient in key DNA repair processes [41, 43].
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An alternative mechanism of toxicity for PARPi has been described, where inhibition of
PARP blocks auto-PARylation and prevents PARP release from DNA [19–23]. We describe
data supporting a model in which EWSCs are hypersensitive to PARP1 trapping. We demon-
strated that an EWSC line with acquired resistance to olaparib had downregulated PARP1 pro-
tein, and siRNA-mediated depletion of PARP1 rescued EWSCs from PARPi hypersensitivity,
indicating that PARP1 protein is required for drug toxicity. Recent reports have observed simi-
lar mechanisms of resistance to PARPi in other cell types [44, 45]. We hypothesized that com-
bination with a chemotherapy agent would drive accumulation of DNA damage in EWSCs,
heightening the recruitment of PARP1 to DNA for SSB repair, and thereby driving enhanced
PARP1 trapping. Cisplatin did not increase sensitivity to PARPi in EWSC, whereas sensitivity
was enhanced with DNA alkylating agents temozolomide and MMS. This is consistent with a
very recent report by Murai et al, published while our studies were on-going [46]. Temozolo-
mide with PARPi increased PARP1 trapping to levels detectable by biochemical assays and
enhanced activation of apoptosis in EWSCs. Since OLAR5 cells, which had downregulated
PARP1 were not hypersensitive to combination of MMS or temozolomide with PARPi, our
data strongly suggest that sensitivity is the result of enhanced PARP1 trapping, likely as a result
of recruitment of PARP1 to DNA in adduct-repair of lesions driven by MMS or temozolomide
[42]. Nevertheless, we cannot rule out that enhanced sensitivity is a result of the combined tox-
icities of DNA lesions caused by MMS and temozolomide, and PARP1 trapping.
Our drug-combination screen and previous studies have demonstrated that DU-145 pros-
tate cancer cells are very sensitive to the combination of temozolomide with PARP inhibition,
and PARP trapping has been demonstrated in these cells [22, 23]. In this current study, we
revealed exquisite sensitivity to the combination of temozolomide with olaparib across multiple
cell lines from different tumour types. PARP trapping may thus be a more general mechanism
of sensitivity to PARPi than so far recognised, potentially extending PARPi use to patients of
multiple tumour types, provided that a biomarker for trapping sensitivity can be identified.
EWSCs highly express PARP1 both at the mRNA and protein level, with its expression sug-
gested to be directly regulated by the EWS-FLI1 fusion protein [47, 48], and EWS-FLI1 expres-
sion induces DNA damage when overexpressed in PC-3 prostate cells [24, 48]. It has been
proposed that olaparib hypersensitivity of EWSCs is due to a combined effect of potentiated
levels of DNA damage and disruption of EWS-FLI1 transcriptional activity [24]. Our data sup-
port olaparib potentiating DNA damage through PARP1 trapping, and although we did not
Fig 6. Temozolomide enhances PARP inhibitor sensitivity in multiple tumour types. List of cell lines
screened against a combination of olaparib and temozolomide. Whether enhancement of PARP inhibitor
sensitivity with temozolomide is observed (✔) or not (✖) is indicated.
doi:10.1371/journal.pone.0140988.g006
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directly assess the effect of PARP inhibition on the EWS-FLI1 transcriptional programme, our
results implicate PARP1 trapping and DNA damage in S-phase as the primary mechanism of
toxicity. By inhibiting cell cycle progression or replication, olaparib-induced DSB breaks are
prevented. Moreover, veliparib, which is a potent inhibitor of PARP enzymatic activity but a
poor trapper, was less toxic in EWSC cells [22]. Thus, we propose that the EWS-FLI1 transcrip-
tional program primes EWSCs for hypersensitivity to PARPi by inducing high PARP1 expres-
sion, increasing the availability of PARP1 for trapping, and elevating basal DNA damage. We
hypothesise that elevated basal DNA damage is managed by a primed DDR but that disruption
of the equilibrium between DNA damage and repair, either through PARP1 trapping or agents
driving cytotoxic DNA lesions, triggers apoptosis. Moreover, it is possible that EWSCs in par-
ticular, are less able to process trapped PARP1 or toxic DSBs at replication forks, making them
distinctively more sensitive to PARP trapping than other cell lines. The mechanism by which
this may occur, however, remains to be elucidated.
When olaparib was tested as a single-agent in 12 adult Ewing’s sarcoma patients with recur-
rent disease as part of a phase II clinical trial, no partial or complete responses were observed [25,
27]. This is consistent with the minimal activity of single-agent PARPi in Ewing’s sarcoma xeno-
grafts, suggesting that PARPi may not trap PARP as efficiently in vivo [24, 28]. Our results pro-
vide mechanistic insights that support on-going trials combining temozolomide with olaparib in
Ewing’s sarcoma patients, a combination already validated in xenograft and orthotopic models
[27–29, 49, 50]. Combination of PARPi with temozolomide would thus be predicted to enhance
the level of PARP1 trapping in Ewing’s sarcoma tumors to achieve greater clinical efficacy.
First-line therapy in Ewing’s sarcoma patients currently consists of a five-drug regimen of
vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide. Cyclophosphamide
and ifosfamide are, like temozolomide, alkylating agents driving lesions likely to be repaired by
PARP1. Thus combination of these agents with PARPi could result in more effective therapy
provided that this combination is tolerated in patients. If so, combining etoposide with alkylat-
ing agents and PARP1 inhibition would potentially suppress resistance mediated through
down-regulation of PARP1, which we have shown can provide a possible route of resistance to
this type of combination therapy.
Our study suggests that PARP1 inhibition should be evaluated in combination with the
standard-of-care multi-chemotherapy regimen to assess its ability to improve treatment out-
comes in Ewing’s sarcoma, with a view to at least delay the onset of recurrent disease. Thus,
our results provide a mechanistic framework to understand the activity of PARPi in EWSCs,
which should help promote the successful development of a targeted therapy for the treatment
of Ewing’s sarcoma.
Supporting Information
S1 Data. Table of cell line drug sensitivity data.
(XLSX)
S2 Data. Table of cell lines with cross-sensitivity to BMN-673, olaparib and camptothecin.
(XLSX)
S1 Fig. Sensitivity of EWSCs to DNA-damaging agents. (A) List of Ewing’s sarcoma cell lines
in which disruption of the EWS gene was confirmed (✔), undetected (✖) or not determined
(ND) by either FISH, PCR or RNA-sequencing. (B) Scatter plots of IC50 (μM) values on a log
scale comparing drug sensitivity of EWS-FLI1-translocation-positive and wild-type (WT) cell
lines to various S-phase damaging agents. Each circle represents the IC50 of one cell line and
the red bar is the geometric mean. The sample size (n) is indicated below each plot and the
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drug name above along with the significance of the association as determined by an unpaired
two-sample t-test.
(TIF)
S2 Fig. DDR proteins are expressed in EWSCs. (A) Expression levels of DDR proteins in
parental ES8 and PARP inhibitor-resistant OLAR5 cells. Tubulin served as a loading control.
(B) Expression of BRCA1 and BRCA2 in BRCA1, BRCA2 and negative control IgG immuno-
precipitates (IP) from Ewing’s (ES7, ES8, MHH-ES-1) and control cell lines. 5% of whole cell
lysates were western blotted (WB) for tubulin to control for variations in IP volume (input).
(TIF)
S3 Fig. The DDR and HR are functional in EWSCs. (A)MHH-ES-1 cells were treated with
olaparib for 16 hours following a 6-hour pre-treatment with palbociclib (CDK4/6i) or vehicle
and percentage of γH2AX responders determined. (B) ES8 cells were treated with vehicle or
olaparib and stained with Hoechst (nucleus; blue) and for 53BP1 (green). Images on the left are
of the 8-hour time point. The graph measures fold increase in 53BP1 responders at the time
points indicated. (C)MHH-ES-1 and ES7 cells were treated with vehicle, 5μM aphidicolin
(AphD), 5μM olaparib (Ola) or a 30-minute pre-treatment with aphidicolin followed by ola-
parib for 8 hours and percentage of γH2AX responders determined. Asterisks indicate student’s
paired t-test P value  (P<0.01), (P<0.001), (P<0.0001), ns = not significant, relative
to control. (D) ES8 cells were labeled with EdU and treated with vehicle or olaparib before fix-
ing and staining for DAPI (grey, nucleus), RAD51 (green), γH2AX (red) and EdU incorpo-
ration (blue, S-phase cells) as indicated. Scale bars are 500μm in size in rows 1–2 and 100μm in
row 3. Error bars represent the standard deviation of the mean of technical triplicates and
results are representative of 3 independent experiments.
(TIF)
S4 Fig. EWSCs are sensitive to PARP1 trapping. (A)Western blot of ES7 and MHH-ES-1
cells treated with olaparib for the times indicated. Markers are grouped as part of ATM or ATR
signaling. Tubulin served as a loading control. (B) Expression levels of PARP1 in cells trans-
fected with two distinct PARP1 siRNAs (1 and 2) or a scrambled control. (C) Relative viability
of mock-transfected and PARP1_1 siRNA-transfected ES8 cells treated with vehicle or ruca-
parib. Asterisks indicate student’s paired t-test P value, P<0.001, ns = not significant. (D)
Relative viability of mock-transfected and PARP1_1 siRNA-transfected ES7 and MHH-ES-1
cells treated with vehicle, olaparib or rucaparib. Asterisks indicate student’s paired t-test P value
P<0.01, ns = not significant. (E) Relative viability of mock-transfected and PARP1 siRNA(1
and 2)-transfected cells treated with vehicle or olaparib. Viability values are the mean of techni-
cal duplicates.
(TIF)
S5 Fig. Combination drug screening results. Ewing’s cells (ES7, A673, MHH-ES-1 and ES8),
the ES8-derived PARP inhibitor-resistant OLAR5 cells, non-Ewing’s control lines (U-2-OS,
DU-145) and a BRCA1-mutant breast cancer cell line (MDA-MB-436) were screened against
titrated concentrations of three different PARP inhibitors (niraparib, rucaparib, BMN-673) in
combination with titrated concentrations of three chemotherapies (camptothecin, cisplatin
and temozolomide) or methyl methanesulfonate (MMS). Heatmaps show relative viability val-
ues of each combination. The PARP inhibitor and relevant concentrations are on the vertical
axis and the chemotherapy or MMS and relevant concentrations are on the horizontal axes.
Drug concentrations are in micromolar (μM) with high viability values in red and low viability
values in green. Viability values are the mean of technical duplicates.
(PDF)
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S6 Fig. Temozolomide enhances PARP inhibitor sensitivity in cancer cells. (A) Relative via-
bility of ES8, ES7 and MHH-ES-1 cells treated with temozolomide (log scale) in the presence
or absence of olaparib. Relative viability is normalized to 0.5μM olaparib and dotted lines indi-
cate the viability of olaparib-only controls. Error bars represent the standard deviation of the
mean of technical triplicates. (B) Relative viability of U-2-OS and DU-145 cells treated with
vehicle, niraparib or temozolomide (TMZ) alone, or in combination. The combination effect is
highlighted in green. (C)Heatmap of relative viability values of OLAR5 cells against a combi-
nation of niraparib and temozolomide (TMZ). High viability values are in red and low viability
values in green. Graph shows the corresponding dose response curves measuring relative via-
bility with a separate line plotted for each concentration of the combined drug. The dose
response for niraparib alone is highlighted in red. Viability values are the mean of technical
duplicates. (D) Relative viability of ES8, ES7 and MHH-ES-1 cells treated with MMS (log scale)
in the presence or absence of olaparib. Relative viability is normalized to 0.5μM olaparib and
dotted lines indicate the viability of olaparib-only controls. Error bars represent the standard
deviation of the mean of technical triplicates. (E)MHH-ES-1 cells were treated with vehicle (-)
or a titration of MMS in combination with olaparib for 2 hours. A cellular sub-fractionation
assay was performed and soluble nuclear and chromatin fractions western blotted for PARP1.
Histone-3 (H3) served as a fractionation control.
(TIF)
S7 Fig. PARPi and temozolomide synergise in glioma, neuroblastoma and melanoma cells.
(A) Relative viability of cells treated with temozolomide (log scale) in the presence or absence
of olaparib for 72 hours, or 6 days where indicated. Data represent technical duplicates. (B)
Cellular sub-fractionation assay following treatment of cells with vehicle (-), MMS in combina-
tion with olaparib (ola), or olaparib and temozolomide (TMZ) alone or in combination for 4
hours. (C) Relative viability of U251 cells treated with temozolomide (log scale) in the presence
or absence of olaparib for 6 days. (D) A cellular sub-fractionation assay in U251 cells.
(TIF)
S1 Text. Supplementary methods.
(DOCX)
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